MESS-study MRSA Eradication Study Skåne

Region Skane

Status: Completed

Conditions: Throatcarriers of MRSA

Treatments: Drug: Rifampin+Clindamycine or Trimehoprimsulfa; Drug: Mupirocin

Study type: Interventional

Funder types: Other

Identifiers

NCT01269541

2010-019727-55 (EudraCT Number)

MRSA-2010

Details and patient eligibility

About

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Enrollment: 69 patients

Sex: All

Ages: 5+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion criteria

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

69 participants in 2 patient groups

Mupirocin

Active Comparator group

Description:

Topical treatment

Treatment:

Drug: Mupirocin

Drug: Rifampin+Clindamycine or Trimehoprimsulfa

Rifampicin+Clindamycine or Trimethoprimsulfa

Active Comparator group

Description:

Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2

Treatment:

Drug: Rifampin+Clindamycine or Trimehoprimsulfa